Total compensation: $8,037,001 for the year ended June 30, 2019
Salary: $957,000
Nonequity incentive pay: $2,008,183
Other compensation: $45,688
Value realized on vesting shares: $5,026,130
New stock options: 60,222
CEO pay ratio: 171-1
Median employee pay: $64,371
Total shareholder return: 41.9%
Note: Kummeth's compensation was the highest since he joined Minneapolis-based Bio-Techne as CEO in April 2013 — and $3.3 million more than the previous year — thanks mainly to $5 million worth of previously issued restricted stock awards that vested last year.
Under Kummeth's leadership, the maker of biotechnology reagents and instruments for research and diagnostic labs made more than a dozen acquisitions and nearly doubled its annual revenue to $714 million for the last fiscal year.
The company's share price has had a total return of 233% during his tenure, outpacing the 88% return of the S&P 500 index. That market outperformance helped increase the value of Kummeth's long-term equity awards.
Kummeth also earned his largest annual performance bonus, $2 million, a 25% increase over the previous year and 159% of the targeted amount for the year.
Patrick Kennedy
Argentine economy minister resigns amid peso, diesel woes

Russians press assault on eastern Ukrainian city

Holiday getaway pushes U.S. airport traffic to pandemic high
UN condemns protesters' storming of Libya's parliament
